Is Kenvue, the Beaten-Down Dividend King, a Buy in Today’s Market?

In an era of economic uncertainty, dividend stocks like Kenvue (KVUE) offer investors a potential hedge. The healthcare specialist, spun off from Johnson & Johnson (JNJ) in 2023, carries the rare distinction of being a Dividend King—a title reserved for companies with 50+ consecutive years of dividend growth. Despite this pedigree, Kenvue shares have slumped 25% year-to-date amid operational challenges.

The company now focuses exclusively on over-the-counter health products, abandoning J&J's pharmaceutical roots. Its portfolio includes household brands in self-care and skincare, but market skepticism persists. Dividend investors face a critical question: does Kenvue's discounted price offset its recent struggles, or does the spin-off signal deeper vulnerabilities?